Q1 EPS Estimates for Daré Bioscience Raised by HC Wainwright

Daré Bioscience, Inc. (NASDAQ:DARE) – Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Daré Bioscience in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst D. Tsao now expects that the biotechnology company will post earnings of ($0.57) per share for the quarter, up from their prior forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Daré Bioscience’s Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at $0.77 EPS and FY2028 earnings at $9.87 EPS.

Daré Bioscience Trading Down 1.4 %

NASDAQ DARE opened at $2.89 on Friday. The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. The stock has a 50-day simple moving average of $3.03 and a 200 day simple moving average of $3.28. Daré Bioscience has a 12 month low of $2.67 and a 12 month high of $7.56.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.02. The business had revenue of ($0.06) million during the quarter, compared to the consensus estimate of $1.00 million.

Institutional Trading of Daré Bioscience

Hedge funds have recently added to or reduced their stakes in the business. AMH Equity Ltd lifted its holdings in shares of Daré Bioscience by 50.0% during the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Daré Bioscience by 6.7% in the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 4,300 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Daré Bioscience during the fourth quarter worth $52,000. Institutional investors and hedge funds own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.